Last reviewed · How we verify
NCT06253559
Clinical and Pathological Characteristics of Women With Ovarian Cancers in Syria
trial in Ovarian Cancer in 531 participants. Completed in 24 December 2023.
31 July 2021
Quick facts
| Lead sponsor | Tishreen University |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 531 |
| Start date | 1 January 2017 |
| Primary completion | 31 July 2021 |
| Estimated completion | 24 December 2023 |
| Sites | 1 location across Syria |
Conditions studied
- Ovarian Cancer — all drugs for Ovarian Cancer →
Sponsor
Tishreen University
Who can join
18 and older, female only, with Ovarian Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
the goal of this observational study is to describe ovarian cancer epidemiology and characteristics in Syrian women, especially during the war to do more research in the future about the risk factors of ovarian cancer.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Epidemiological and clinicopathological characteristics of ovarian cancer in Syria during the war years: a national multicenter retrospective study (2017-2021).
Apelian S, Hamdan A, Mohammad R, Abbas A, et al · · 2025 · PMID 40847388 · DOI 10.1186/s12885-025-14784-8
Verify or expand the search:
- PubMed search for NCT06253559
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Ovarian Cancer
Currently open trials in the same condition.
- NCT06412120 — Study Evaluating Safety, Tolerability, and Metabolism of Niraparib · Phase 4 · recruiting
- NCT06930755 — Study of NMS-03305293 in Adult Patients With Relapsed Ovarian Cancer · Phase 1 · recruiting
- NCT07318558 — A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021) · Phase 3 · recruiting
- NCT07491081 — EARLY Study: Evaluating the Specificity and Feasibility of the EARLY Biomarker Panel for Ovarian Cancer Detection · NA · recruiting
- NCT07410676 — EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
Other Tishreen University trials
Trials by the same sponsor.
- NCT07350421 — The Effectiveness of Inhaled Salbutamol in the Management of Transient Tachypnea of the Newborn(TTN) · NA · not yet recruiting
- NCT07270042 — Evaluation the Efficacy of Zinc on Botulinum Toxin A Injection · NA · not yet recruiting
- NCT07099261 — A Comparative Clinical Study to Evaluate Crowns Designed by Artificial Intelligence Versus Crowns Designed Traditional D · NA · not yet recruiting
- NCT07467759 — Benzydamine for Radiation-Induced Oral Mucositis in Patients Receiving High-Dose Radiotherapy · Phase 4 · completed
- NCT07095946 — Effectiveness of Intraligament vs IANB Anesthesia in Children Using Electronic Syringe · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06253559 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Tishreen University
- Last refreshed: 15 February 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06253559.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing